Related Experiment Video
Updated: Apr 27, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Oncogenes associated with drug resistance in ovarian cancer
1Center for Translational Medicine, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, Guangxi, People's Republic of China.
Purpose:
Oncogenes play pivotal roles in the development of cancer, and disturbances in their expression have been implicated in drug resistance. However, an overview of the contribution of oncogenes to drug resistance in ovarian cancer has not previously been reported. This study aimed to review the drug resistance-related oncogenes in ovarian cancer and precisely determine their relationships.
Methods:
The oncogenes associated with drug resistance in ovarian cancer from available papers were summarized, and a comprehensive bioinformatics analysis including pathway enrichment, biological processes annotation, protein/gene interaction and microRNA-mRNA interaction was performed.
Results:
Total of 25 oncogenes contributing to drug resistance in ovarian cancer was integrated and further analyzed. An oncogene-mediated drug resistance pathway that explains the associations of 21 of these oncogenes in drug resistance was drafted on the basis of previously published papers. The downstream location of v-akt murine thymoma viral oncogene (AKT) and B-cell CLL/lymphoma 2-associated X protein (BAX) with respect to many other oncogenes was determined, indicating that the two genes may play a central role, and the AKT- and BAX-mediated signaling are the main pathways accounting for the involvement of oncogenes in drug resistance in ovarian cancer. Besides, the annotation of biological process indicated that the apoptosis (cell death) and phosphorylation (phosphate metabolic process) might be the two major biological routes through which oncogenes contribute to drug resistance in ovarian cancer. In addition, on the basis of the comprehensive analysis of microRNA-mRNA interactions, 11 microRNAs were identified to be targeted at least 7 of the 25 oncogenes, indicating that those microRNAs could be an important regulator of the 25 oncogenes. Collectively, by integrating and further analyzing the available data on these oncogenes, this study contributes to improving our understanding of the mechanisms by which their expression leads to drug resistance in this ovarian cancer.
Insights
This study identifies 25 oncogenes contributing to drug resistance in ovarian cancer. Key pathways involve AKT and BAX signaling, impacting apoptosis and phosphorylation, offering insights into overcoming treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Oncogenes are crucial in cancer development and drug resistance.
- Ovarian cancer drug resistance mechanisms involving oncogenes require further elucidation.
- A comprehensive overview of oncogenes in ovarian cancer drug resistance is lacking.
Purpose of the Study:
- To review and analyze oncogenes associated with drug resistance in ovarian cancer.
- To determine the relationships and pathways through which oncogenes contribute to drug resistance.
- To identify potential regulatory microRNAs targeting these oncogenes.
Main Methods:
- Literature review to identify relevant oncogenes.
- Bioinformatics analysis including pathway enrichment and biological process annotation.
- Investigation of protein/gene and microRNA-mRNA interactions.
Main Results:
- 25 oncogenes contributing to ovarian cancer drug resistance were identified and analyzed.
- A drug resistance pathway involving 21 oncogenes was drafted, highlighting AKT and BAX as central.
- Apoptosis and phosphorylation were identified as key biological processes, and 11 microRNAs targeting these oncogenes were found.
Conclusions:
- Oncogenes, particularly through AKT and BAX signaling, significantly contribute to ovarian cancer drug resistance.
- Understanding these oncogene-mediated pathways, including apoptosis and phosphorylation, is critical for developing new therapeutic strategies.
- Targeting identified microRNAs may offer a novel approach to modulate oncogene expression and overcome drug resistance in ovarian cancer.
Related Concept Videos
02:56Treatment Resistant Cancers
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
02:56Treatment Resistent Cancers